Veterans

In recent years, a quiet revolution has been unfolding within the realm of treatment for combat-related injuries: psychedelic therapies. Substances like MDMA, psilocybin and ibogaine are now at the forefront of cutting-edge research for their potential to alleviate severe conditions, particularly post-traumatic stress (PTS) and post-traumatic stress disorder (PTSD).

WASHINGTON — House lawmakers on Tuesday demanded the resignation of Shereef Elnahal, undersecretary for health at the Department of Veterans Affairs, for withholding information from the VA secretary about plans to give large bonuses to senior managers meant for rank-and-file workers.

During a hearing of the House Veterans’ Affairs Committee, Rep. Derrick Van Orden, R-Wis., presented VA Secretary Denis McDonough with a resignation letter for Elnahal’s signature.

A former Navy SEAL-turned-congressman says the FDA's decision bashing psychedelics to threat PTSD is a 'poor decision' because the therapies saved his own life. 

A group of Republican and Democrat congressional lawmakers has come together to ask the U.S. Department of Veterans Affairs (VA) to create a plan to implement therapy using MDMA for veterans should it be approved by the FDA. The bipartisan group of nine U.S.

Biden should loosen restrictions to allow veterans to use psychedelics as they recover from trauma experienced in combat, say lawmakers. 

One illegal drug, commonly known as 'Molly,' that's popular among partiers and rave-goers has recently been found to be helpful in treating mental health issues.

WASHINGTON — The U.S. Food and Drug Administration has agreed to review a new drug application for MDMA — commonly known as ecstasy — to be developed for the treatment of post-traumatic stress disorder in a supervised clinical setting.

Lykos Therapeutics, a biotechnology research company in San Jose, Calif., announced the FDA granted priority review status for its new drug application for midomafetamine, or MDMA, capsules as a medical treatment for PTSD.